CONUT评分对新辅助治疗后非小细胞肺癌切除患者的预后意义及预测列线图开发
单中心回顾性队列纳入226例II-III期非小细胞肺癌患者,均接受至少1周期新辅助系统治疗并后续行根治性肺切除。新辅助治疗前CONUT评分较高者术后OS与DFS更差(多因素HR 3.759,95%CI 2.189-6.455,p<0.001),并在化疗与化疗免疫治疗亚组及替代阈值敏感性分析中一致。所建列线图区分度与校准可接受,可用于术后风险分层与随访规划。
要点
- 新辅助治疗前CONUT评分较高与非小细胞肺癌术后OS、DFS更差独立相关。
- 多因素HR 3.759(95%CI 2.189-6.455,p<0.001),化疗与化疗免疫治疗亚组结果一致。
- 列线图在临床相关时间点区分度与校准可接受,可用于术后风险分层与个体化随访。
核心结论
- 新辅助治疗前CONUT评分是非小细胞肺癌接受新辅助治疗患者长期结局的独立且稳健预测因子。
- 所开发列线图有助于术后风险分层和个体化随访规划。
研究设计与样本
- 单中心三级中心回顾性队列研究,共纳入226例患者。
- 纳入标准为II-III期非小细胞肺癌、接受至少1周期新辅助系统治疗并后续行根治性肺切除。
- 排除仅接受新辅助放疗的患者,营养与炎症指标在新辅助治疗前获取。
主要发现
- 新辅助治疗前CONUT评分较高者术后OS与DFS更差(多因素HR 3.759,95%CI 2.189-6.455,p<0.001)。
- 结果在化疗和化疗免疫治疗亚组中一致,并在替代阈值敏感性分析中一致。
- 预测模型在临床相关时间点显示可接受的区分度与校准。
临床怎么用
- 可在新辅助治疗前检测CONUT评分,用于非小细胞肺癌术后风险分层。
- 结合列线图识别高危患者,个体化安排术后随访。
局限性
- 单中心回顾性设计。
- 原文未报告具体样本特征、随访时长及模型验证细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate whether the Controlling Nutritional Status (CONUT) score measured before the start of neoadjuvant therapy is associated with overall survival (OS) and disease-free survival (DFS) after lung resection for non-small-cell lung cancer, and to present a clinically usable prediction tool. METHODS: This was a retrospective cohort study at a single tertiary centre. Eligible patients had stage II-III non-small-cell lung cancer, received at least 1 cycle of neoadjuvant systemic therapy, and subsequently underwent definitive pulmonary resection. Patients treated with neoadjuvant radiotherapy alone were excluded. Nutritional and inflammatory indices were obtained before neoadjuvant therapy. The primary end-points were OS and DFS. Associations and model performance were assessed using prespecified multivariable analyses and standard validation procedures. RESULTS: A total of 226 patients were included. Patients with a higher CONUT score before neoadjuvant therapy had worse OS and DFS after surgery (multivariable hazard ratio 3.759, 95% confidence interval 2.189-6.455, p < 0.001). Findings were consistent across treatment subgroups (chemotherapy and chemoimmunotherapy) and in sensitivity analyses using alternative thresholds. The prediction model showed acceptable discrimination and calibration at clinically relevant time points. CONCLUSIONS: The CONUT score is an independent and robust predictor of long-term outcomes in non-small cell lung cancer patients receiving neoadjuvant therapy. The developed nomogram is useful for postoperative risk stratification and individualized follow-up planning. Future studies should explore the integration of multiple nutritional and inflammatory markers into AI-based prognostic models to enhance predictive accuracy.
引用
- Yuan W, Huang Q, Yan X, et al. Prognostic Significance of the Controlling Nutritional Status Score in Non-Small Cell Lung Cancer Patients Undergoing Neoadjuvant Therapy: Development of a Predictive Nomogram. Eur J Cardiothorac Surg. 2025. PMID: 41339277. doi:10.1093/ejcts/ezaf436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。